Matthew T. Wiley

Insider Reports History

Location
Rehovot
Signature
/s/Mark Sullivan, Attorney-in-Fact for Matthew T. Wiley
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew T. Wiley:

Form 4 holding Chief Commercial Officer

VYNE Therapeutics Inc.

Security class
Common Stock
Shares / value
109,246
Estimated value
$249,081
Report date
30 Jun 2021
Price
$2.28
Ownership
Direct
Form 4 holding Chief Commercial Officer

BioXcel Therapeutics, Inc.

Security class
Common Stock
Shares / value
19,011
Estimated value
$10,456
Report date
03 Oct 2024
Price
$0.5500
Ownership
Direct
Form 4 holding Chief Commercial Officer

BioXcel Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
7,500
Estimated value
$9,600
Report date
15 Sep 2024
Price
$1.28
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Commercial Officer

Mind Medicine (MindMed) Inc.

Security class
Stock Option (Right to Buy)
Shares / value
350,000
Estimated value
Report date
17 Mar 2025
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Chief Commercial Officer

BioXcel Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
1,875
Estimated value
Report date
22 Jul 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Matthew T. Wiley

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .